Last reviewed · How we verify
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Details
| Lead sponsor | Nanjing Leads Biolabs Co.,Ltd |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 140 |
| Start date | Mon Oct 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Dec 26 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Solid Tumour
Interventions
- LBL-024 for Injection
- Cisplatin Injection
- Gemcitabine Hydrochloride for Injection
- Bevacizumab Injection
Countries
China